PE20040952A1 - N-ARYLHETERO CYCLES SUBSTITUTED AND PROCEDURES FOR THEIR PREPARATION - Google Patents
N-ARYLHETERO CYCLES SUBSTITUTED AND PROCEDURES FOR THEIR PREPARATIONInfo
- Publication number
- PE20040952A1 PE20040952A1 PE2004000158A PE2004000158A PE20040952A1 PE 20040952 A1 PE20040952 A1 PE 20040952A1 PE 2004000158 A PE2004000158 A PE 2004000158A PE 2004000158 A PE2004000158 A PE 2004000158A PE 20040952 A1 PE20040952 A1 PE 20040952A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- phenyl
- preparation
- pyrrolidin
- phenoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
SE REFIERE A N-ARILHETEROCICLOS SUSTITUIDOS DE FORMULA I DONDE R1 Y R2 SON H, ALQUILO C1-C8, -(CR78R79)o-R12, (ALCOXI C1-C4)(ALQUILO C1-C4), ARILOXI-(ALQUILO C1-C4), ALQUENILO C3-C8, ALQUINILO C3-C8, ENTRE OTROS; o ES 0-6; p ES 0-2; q, r, s SON 0-4; R13 Y R14 SON UN SISTEMA AROMATICO DE 5-10 ESLABONES CON 0-2 HETEROATOMOS: R15 A R17 Y R19 A R32 SON H, ALQUILO C1-C6; R18 ES H, ALQUILO C1-C6, CO(ALQUILO C1-C6) ENTRE OTROS; R12 ES OH, O-(ALQUILO C1-C6), O-(ALQUILEN C0-C8)-ARILO, ENTRE OTROS; R3 ES H, ALQUILO C1-C6; R4 Y R5 SON H, ALQUILO C1-C6, OH, ENTRE OTROS; R6 A R9 ES H, ALQUILO C1-C8; n, m SON 0 A 2; A, B, D, G SON N, C(R42); R42 ES H, HALO, OH, CF3, ENTRE OTROS; X ES N(R52) Y R52 ES H, ALQUILO C1-C8; E ES UN HETEROCICLICO; K ES UN ENLACE, O, OCH2, S, ENTRE OTROS;R10 ES H, ALQUILO C1-C8, ALQUENILO C3-C6; R11 ES H, ALQUILO C1-C8, ENTRE OTROS; R78 Y R79 SON H, ALQUILO C1-C6. SON COMPUESTOS PREFERIDOS N-METIL-N-(1-{4-[3-(4-FENOXI-FENIL)-UREIDO]-FENIL}-PIRROLIDIN-3-IL)ACETAMIDA; 1-[4-(3-METILAMINO-PIRROLIDIN-IL)-FENIL]-3-(4-FENOXI-FENIL)-UREA; N-METIL-N-(1-{4-[3-(4-FENOXI-FENIL)-UREIDO]-FENIL}-PIRROLIDIN-3-IL)-2-FENIL-ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS SON UTILES PARA EL TRATAMIENTO DE LA OBESIDAD Y DIABETESREFERS TO N-ARYLHETEROCYCLES SUBSTITUTED FOR FORMULA I WHERE R1 AND R2 ARE H, C1-C8 ALKYL, - (CR78R79) or -R12, (C1-C4 ALCOXI) (C1-C4 ALKYL), ARYLOXY- (C1-C4 ALKYL ), C3-C8 ALKENYL, C3-C8 ALKYNYL, AMONG OTHERS; or ES 0-6; p IS 0-2; q, r, s ARE 0-4; R13 AND R14 ARE A 5-10 LINK AROMATIC SYSTEM WITH 0-2 HETEROATOMS: R15 TO R17 AND R19 TO R32 ARE H, C1-C6 ALKYL; R18 IS H, C1-C6 ALKYL, CO (C1-C6 ALKYL) AMONG OTHERS; R12 IS OH, O- (C1-C6 ALKYL), O- (C0-C8 ALKYLENE) -ARYL, AMONG OTHERS; R3 IS H, C1-C6 ALKYL; R4 AND R5 ARE H, C1-C6 ALKYL, OH, AMONG OTHERS; R6 TO R9 IS H, C1-C8 ALKYL; n, m ARE 0 TO 2; A, B, D, G ARE N, C (R42); R42 IS H, HALO, OH, CF3, AMONG OTHERS; X IS N (R52) AND R52 IS H, C1-C8 ALKYL; E IS A HETERO CYCLIC; K IS A LINK, O, OCH2, S, AMONG OTHERS, R10 IS H, C1-C8 ALKYL, C3-C6 ALKYL; R11 IS H, C1-C8 ALKYL, AMONG OTHERS; R78 AND R79 ARE H, C1-C6 ALKYL. PREFERRED COMPOUNDS ARE N-METHYL-N- (1- {4- [3- (4-PHENOXY-PHENYL) -UREIDO] -PHENYL} -PYRROLIDIN-3-IL) ACETAMIDE; 1- [4- (3-METHYLAMINO-PYRROLIDIN-IL) -PHENYL] -3- (4-PHENOXY-PHENYL) -UREA; N-METHYL-N- (1- {4- [3- (4-PHENOXY-PHENYL) -UREIDO] -PHENYL} -PYRROLIDIN-3-IL) -2-PHENYL-ACETAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. THE MENTIONED COMPOUNDS ARE USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10306250A DE10306250A1 (en) | 2003-02-14 | 2003-02-14 | Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20040952A1 true PE20040952A1 (en) | 2005-02-08 |
Family
ID=32841665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004000158A PE20040952A1 (en) | 2003-02-14 | 2004-02-13 | N-ARYLHETERO CYCLES SUBSTITUTED AND PROCEDURES FOR THEIR PREPARATION |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP1597228A2 (en) |
JP (1) | JP2006517563A (en) |
KR (1) | KR20050101215A (en) |
CN (1) | CN100506792C (en) |
AR (1) | AR044496A1 (en) |
AU (1) | AU2004212145B2 (en) |
BR (1) | BRPI0407504A (en) |
CA (1) | CA2516118A1 (en) |
CO (1) | CO5690548A2 (en) |
DE (1) | DE10306250A1 (en) |
EC (1) | ECSP055967A (en) |
HR (1) | HRP20050710A2 (en) |
MA (1) | MA27735A1 (en) |
MX (1) | MXPA05008449A (en) |
MY (1) | MY139102A (en) |
NO (1) | NO20054220L (en) |
NZ (1) | NZ541823A (en) |
OA (1) | OA13027A (en) |
PA (1) | PA8595901A1 (en) |
PE (1) | PE20040952A1 (en) |
PL (1) | PL378065A1 (en) |
RS (1) | RS20050666A (en) |
RU (1) | RU2005128551A (en) |
TN (1) | TNSN05194A1 (en) |
TW (1) | TW200510297A (en) |
UA (1) | UA86760C2 (en) |
UY (1) | UY28186A1 (en) |
WO (1) | WO2004072025A2 (en) |
ZA (1) | ZA200506369B (en) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
EP2251343A1 (en) | 2003-05-15 | 2010-11-17 | Arqule, Inc. | Imidazothiazoles as p38-kinase-inhibitors |
WO2005009988A1 (en) | 2003-07-24 | 2005-02-03 | Euro-Celtique S.A. | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
PL1867644T3 (en) * | 2003-07-24 | 2009-10-30 | Euro Celtique Sa | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
EP2426120A1 (en) | 2003-08-18 | 2012-03-07 | Fujifilm Finechemicals Co., Ltd. | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them |
DE10360745A1 (en) * | 2003-12-23 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New amide compounds having MCH antagonist activity and medicaments containing these compounds |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE102004003812A1 (en) * | 2004-01-25 | 2005-08-11 | Aventis Pharma Deutschland Gmbh | Aryl-substituted heterocycles, methods of their preparation and their use as pharmaceuticals |
US7319108B2 (en) | 2004-01-25 | 2008-01-15 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
WO2006010082A1 (en) * | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
WO2006022442A1 (en) * | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | Novel heterocyclic amide derivatives having dihydroorotate dehydrogenase inhibiting activity |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
MX2007003321A (en) * | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents. |
CA2582327A1 (en) | 2004-10-01 | 2006-04-13 | Takao Suzuki | 2-arylcarboxamide-nitrogeneous heterocycle compound |
US7868014B2 (en) | 2004-10-18 | 2011-01-11 | Eli Lilly And Company | 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists |
CA2584368A1 (en) | 2004-10-19 | 2006-04-27 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
DE102004051277A1 (en) | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclic carbonyl compounds |
JPWO2006054793A1 (en) * | 2004-11-19 | 2008-06-05 | 財団法人新産業創造研究機構 | Benzofuran compound and pharmaceutical composition containing the same |
UY29321A1 (en) | 2004-12-30 | 2006-03-31 | Janssen Pharmaceutica Nv | PIPERAZINILUREAS AND PIPERIDINILUREAS AS AMID HYDROLASSES MODULATORS OF FATTY ACIDS |
AU2006208043B2 (en) | 2005-01-25 | 2012-09-20 | Synta Pharmaceuticals Corp. | Thiophene compounds for inflammation and immune-related uses |
DE602006006463D1 (en) | 2005-09-30 | 2009-06-04 | Hoffmann La Roche | INDANDERIVATES AS ANTAGONISTS OF THE MCH RECEPTOR |
EP1987028A2 (en) | 2006-02-10 | 2008-11-05 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
CN101384605A (en) * | 2006-02-15 | 2009-03-11 | 塞诺菲-安万特股份有限公司 | Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
KR20080095879A (en) * | 2006-02-15 | 2008-10-29 | 사노피-아벤티스 | Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
TWI417095B (en) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors |
WO2007123269A1 (en) * | 2006-04-19 | 2007-11-01 | Astellas Pharma Inc. | Azolecarboxamide derivative |
WO2007121484A2 (en) | 2006-04-19 | 2007-10-25 | Novartis Ag | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
UA93548C2 (en) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Compounds and compositions as hedgehog pathway modulators |
US8461167B2 (en) * | 2006-05-08 | 2013-06-11 | Ariad Pharmaceuticals, Inc. | Acetylenic heteroaryl compounds |
KR101441365B1 (en) | 2006-05-08 | 2014-09-18 | 어리어드 파마슈티칼스, 인코포레이티드 | Monocyclic heteroaryl compounds |
CA2666193A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use |
CN101506203B (en) * | 2006-08-24 | 2013-10-16 | 诺瓦提斯公司 | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other syndromes |
US7691893B2 (en) | 2006-09-11 | 2010-04-06 | Glaxo Group Limited | Chemical compounds |
JP2010504362A (en) * | 2006-09-25 | 2010-02-12 | アレテ セラピューティクス, インコーポレイテッド | Soluble epoxide hydrolase inhibitor |
AR063311A1 (en) * | 2006-10-18 | 2009-01-21 | Novartis Ag | ORGANIC COMPOUNDS |
US7759344B2 (en) * | 2007-01-09 | 2010-07-20 | Amgen Inc. | Bis-aryl amide derivatives and methods of use |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
GB0706793D0 (en) * | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
RU2470017C2 (en) * | 2007-06-08 | 2012-12-20 | Янссен Фармацевтика Н.В. | Piperidine/piperazine derivatives |
CA2687912C (en) | 2007-06-08 | 2015-11-03 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine/Piperazine derivatives |
JP5464709B2 (en) | 2007-06-08 | 2014-04-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Piperidine / piperazine derivatives |
TWI452044B (en) * | 2007-06-15 | 2014-09-11 | Mitsubishi Tanabe Pharma Corp | Morpholine derivative |
TW200918521A (en) * | 2007-08-31 | 2009-05-01 | Astrazeneca Ab | Heterocyclic amides and methods of use thereof |
BRPI0817101A2 (en) | 2007-09-14 | 2017-05-09 | Addex Pharmaceuticals Sa | 1,3-disubstituted 4- (aryl-x-phenyl) -1h-pyridin-2-ones |
ATE496906T1 (en) | 2007-09-14 | 2011-02-15 | Ortho Mcneil Janssen Pharm | 1',3'-DISUBSTITUTED 4-PHENYL-3,4,5,6-TETRAHYDRO-2H,1'H-Ä1,4'ÜBIPYRI INYL-2'-ONE |
CN101801930B (en) | 2007-09-14 | 2013-01-30 | 奥梅-杨森制药有限公司 | 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones |
PL2212282T3 (en) * | 2007-10-17 | 2012-02-29 | Sanofi Sa | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof |
PT2215058E (en) * | 2007-10-17 | 2012-03-06 | Sanofi Sa | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof |
PT2205558E (en) * | 2007-10-17 | 2012-11-02 | Sanofi Sa | Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators |
PL2212283T3 (en) * | 2007-10-17 | 2012-01-31 | Sanofi Sa | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof |
CA2703106C (en) | 2007-10-24 | 2015-12-01 | Astellas Pharma Inc. | Azolecarboxamide derivatives as trka inhibitors |
WO2009062676A2 (en) | 2007-11-14 | 2009-05-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
EP2070924A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine |
EP2070916A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | 2-Arylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine |
EP2070925A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | New 2-substituted tiazol-4-carboxylic acid derivatives, their manufacture and use as medicine |
RU2364597C1 (en) | 2007-12-14 | 2009-08-20 | Андрей Александрович Иващенко | HETEROCYCLIC INHIBITORS OF Hh-SYGNAL CASCADE, BASED ON THEM MEDICINAL COMPOSITIONS AND METHOD OF TREATING DISEASES INDUCED BY ABBARANT ACTIVITY OF Hh-SIGNAL SYSTEM |
JP5579170B2 (en) * | 2008-06-05 | 2014-08-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Pharmaceutical combination comprising a DGAT inhibitor and a PPAR agonist |
EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
EP2344470B1 (en) | 2008-09-02 | 2013-11-06 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
WO2010033349A1 (en) * | 2008-09-16 | 2010-03-25 | Merck & Co., Inc. | Phthalimide derivative metabotropic glutamate r4 ligands |
JP2012006837A (en) * | 2008-09-30 | 2012-01-12 | Mochida Pharmaceut Co Ltd | 2-indoleacrylamide analogue |
RU2517181C2 (en) | 2008-10-16 | 2014-05-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Indole and benzomorpholine derivatives as modulator of metabotropic glutamate receptors |
AU2009314631B2 (en) | 2008-11-12 | 2014-07-31 | Takeda Pharmaceutical Company Limited | Pyrazinopyrazines and derivatives as kinase inhibitors |
BRPI0921333A2 (en) | 2008-11-28 | 2015-12-29 | Addex Pharmaceuticals Sa | indole and benzoxazine derivatives as metabotropic glutamate receptor modulators |
AR074466A1 (en) * | 2008-12-05 | 2011-01-19 | Sanofi Aventis | PIPERIDINE ESPIRO PIRROLIDINONA AND PIPERIDINONA REPLACED AND ITS THERAPEUTIC USE IN DISEASES MEDIATED BY THE MODULATION OF H3 RECEPTORS. |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
WO2010101247A1 (en) | 2009-03-05 | 2010-09-10 | 塩野義製薬株式会社 | Cyclohexane derivative having npy y5 receptor antagonism |
US8889674B2 (en) | 2009-03-05 | 2014-11-18 | Shionogi & Co., Ltd. | Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism |
BRPI1010831A2 (en) | 2009-05-12 | 2016-04-05 | Addex Pharmaceuticals Sa | 1,2,4-triazolo [4,3-a] pyridine derivatives and their as positive allosteric modulators of mglur2 receptors |
KR101753826B1 (en) | 2009-05-12 | 2017-07-04 | 얀센 파마슈티칼즈, 인코포레이티드 | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
DK2470552T3 (en) | 2009-08-26 | 2014-02-17 | Sanofi Sa | NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE |
WO2011060026A1 (en) | 2009-11-12 | 2011-05-19 | Jansen Pharmaceutica Nv | Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
UA108233C2 (en) | 2010-05-03 | 2015-04-10 | Fatty acid amide hydrolysis activity modulators | |
WO2011143162A1 (en) * | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof |
WO2011143150A1 (en) * | 2010-05-11 | 2011-11-17 | Sanofi | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof |
EP2569304A1 (en) * | 2010-05-11 | 2013-03-20 | Sanofi | Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
UY33469A (en) | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | COMPOSITIONS AND METHODS TO MODULATE THE WNT SIGNALING ROAD |
EP2643320B1 (en) | 2010-11-08 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JP5852666B2 (en) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor |
PT2649069E (en) | 2010-11-08 | 2015-11-20 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
EP2683700B1 (en) | 2011-03-08 | 2015-02-18 | Sanofi | Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120053A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683698B1 (en) | 2011-03-08 | 2017-10-04 | Sanofi | Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120050A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012170561A1 (en) * | 2011-06-06 | 2012-12-13 | The Scripps Research Institute (T.S.R.I.) | N-benzylindole modulators of pparg |
US8957093B2 (en) | 2011-06-06 | 2015-02-17 | The Scripps Research Institute | N-biphenylmethylindole modulators of PPARG |
WO2013078240A1 (en) | 2011-11-22 | 2013-05-30 | Ripka Amy S | N-biphenylmethylbenzimidazole modulators of pparg |
WO2013085954A1 (en) | 2011-12-06 | 2013-06-13 | Janssen Pharmaceutica Nv | Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors |
WO2013085957A1 (en) | 2011-12-06 | 2013-06-13 | Janssen Pharmaceutica Nv | Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors |
CA2873075A1 (en) * | 2012-05-11 | 2013-07-14 | Abbvie Inc. | Nampt inhibitors |
US9499539B2 (en) | 2012-11-05 | 2016-11-22 | Nantbioscience, Inc. | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway |
WO2014134391A1 (en) | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
AR094929A1 (en) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | DERIVATIVES OF PHENYLPIRAZOL AS POWERFUL INHIBITORS OF ROCK1 AND ROCK2 |
JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
CN109999025A (en) | 2014-01-21 | 2019-07-12 | 詹森药业有限公司 | Positive allosteric modulator or the combination of normotopia agonist including metabotropic glutamate energy receptor subtype 2 and application thereof |
NZ722385A (en) | 2014-01-21 | 2019-11-29 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
US10016394B2 (en) | 2014-04-16 | 2018-07-10 | The Scripps Research Institute | PPARG modulators for treatment of osteoporosis |
MX2017000613A (en) * | 2014-07-16 | 2017-04-27 | Novogen ltd | Functionalised and substituted indoles as anti-cancer agents. |
EP3183248B1 (en) * | 2014-08-21 | 2020-11-11 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
JP2017526706A (en) * | 2014-09-10 | 2017-09-14 | エピザイム,インコーポレイティド | Isoxazole carboxamide compounds |
KR20180044384A (en) * | 2015-08-28 | 2018-05-02 | 그렌마크 파머수티칼스 에스. 아. | As a ROR gamma modulator, novel carbocyclic compounds |
SI3430010T1 (en) | 2016-03-17 | 2020-10-30 | F. Hoffmann-La Roche Ag | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
CN108815167B (en) * | 2017-05-24 | 2021-04-13 | 四川晶华生物科技有限公司 | Application of compound in preparing medicine for treating tumor |
TW202136238A (en) * | 2020-01-06 | 2021-10-01 | 大陸商廣東東陽光藥業有限公司 | ROR[gamma]T inhibitor, preparation method therefor and use thereof |
CN115160269A (en) * | 2021-04-02 | 2022-10-11 | 北京大学 | Arylcarboxamide derivatives as positive allosteric modulators of NMDAR |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2663336B1 (en) | 1990-06-18 | 1992-09-04 | Adir | NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. |
EP0788498B1 (en) * | 1994-10-26 | 2001-08-16 | PHARMACIA & UPJOHN COMPANY | Phenyloxazolidinone antimicrobials |
PL327938A1 (en) | 1996-01-17 | 1999-01-04 | Novo Nordisk As | Derivatives of 1,2,4-thiadiazine and 1,4-thiazine, their production and application |
CZ300837B6 (en) | 1996-08-30 | 2009-08-26 | Novo Nordisk A/S | GLP-1 (7-37) derivatives or analogs thereof, pharmaceutical composition in which the derivatives are comprised as well as their use |
PT958296E (en) | 1996-12-31 | 2003-11-28 | Reddys Lab Ltd Dr | HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND ITS UTILIZATION IN THE TREATMENT OF RELATED DIABETES AND DISEASES |
DE19726167B4 (en) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, process for its preparation and pharmaceutical preparation containing it |
HUP0003999A3 (en) | 1997-07-16 | 2003-03-28 | Novo Nordisk As | Fused 1,2,4-thiadiazine derivatives, their preparation, their use and pharmaceutical compositions containing them |
CO4970713A1 (en) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | DERIVATIVES OF CARBOXAMIDOTIAZOLES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
AU1296899A (en) * | 1997-11-07 | 1999-05-31 | Schering Corporation | Phenyl-alkyl-imidazoles as h3 receptor antagonists |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19845405C2 (en) | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Aryl-substituted propanolamine derivatives and their use |
WO2000035454A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
AU2460600A (en) * | 1999-02-10 | 2000-08-29 | Mitsubishi Pharma Corporation | Amide compounds and medicinal use thereof |
PL350907A1 (en) * | 1999-04-09 | 2003-02-10 | Astrazeneca Ab | Adamantane derivatives |
WO2000063208A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
WO2000066585A1 (en) | 1999-04-30 | 2000-11-09 | Neurogen Corporation | 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS |
GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
SE9901875D0 (en) * | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
JP2003502369A (en) | 1999-06-18 | 2003-01-21 | メルク エンド カムパニー インコーポレーテッド | Arylthiazolidinedione derivatives and aryloxazolidinedione derivatives |
MXPA02000973A (en) | 1999-07-29 | 2002-07-30 | Lilly Co Eli | Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists. |
CN1372541A (en) | 1999-09-01 | 2002-10-02 | 阿文蒂斯药物德国有限公司 | Sulfonyl carboxamide derivatives, method for their production and their use as medicaments |
ES2287120T3 (en) | 2000-04-28 | 2007-12-16 | Asahi Kasei Pharma Corporation | NEW BICYCLE COMPOUNDS. |
DE60115227T2 (en) | 2000-05-11 | 2006-08-24 | Bristol-Myers Squibb Co. | TETRAHYDROISOCHINOLINE ANALOGUE AS GROWTH HORMONE SECRETAGOGA |
EP1289526A4 (en) | 2000-05-30 | 2005-03-16 | Merck & Co Inc | Melanocortin receptor agonists |
RU2292345C9 (en) * | 2000-07-17 | 2007-05-10 | Ранбакси Лабораторис Лимитед | Oxazolidinone derivatives |
US6525202B2 (en) * | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
MXPA03000923A (en) * | 2000-07-31 | 2003-06-09 | Smithkline Beecham Plc | Carboxamide compounds and their use as antagonists of a human 11cby receptor. |
JO2654B1 (en) * | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Polyarylcarboxamides useful as lipid lowering agents |
JO2409B1 (en) * | 2000-11-21 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Biphenylcarboxamides useful as lipid lowering agents |
JP2002338537A (en) * | 2001-05-16 | 2002-11-27 | Mitsubishi Pharma Corp | Amide compound and its medicinal use |
WO2002098839A1 (en) * | 2001-06-01 | 2002-12-12 | Tanabe Seiyaku Co., Ltd. | Biphenylcarboxamides and process for preparation thereof |
WO2002098871A1 (en) * | 2001-06-01 | 2002-12-12 | Tanabe Seiyaku Co., Ltd. | Phenylcarboxamides and process for preparation thereof |
AU2002346048A1 (en) * | 2001-06-07 | 2002-12-16 | Merck And Co., Inc. | Benzodiazepine bradykinin antagonists |
DE10142734A1 (en) | 2001-08-31 | 2003-03-27 | Aventis Pharma Gmbh | New (((oxazolylalkyl)-cycloalkyl)-alkyl)-benzoic acid derivatives, are peroxisome proliferator activated receptor agonists or antagonists used e.g. for treating lipid metabolism disorders, type II diabetes, syndrome X and obesity |
AU2003227437A1 (en) * | 2002-04-23 | 2003-11-10 | Shionogi And Co., Ltd. | PYRAZOLO(1,5-a)PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME |
JP2004175739A (en) * | 2002-11-28 | 2004-06-24 | Tanabe Seiyaku Co Ltd | Medicinal composition |
-
2003
- 2003-02-14 DE DE10306250A patent/DE10306250A1/en not_active Withdrawn
-
2004
- 2004-02-13 UY UY28186A patent/UY28186A1/en unknown
- 2004-02-13 NZ NZ541823A patent/NZ541823A/en unknown
- 2004-02-13 KR KR1020057014989A patent/KR20050101215A/en not_active Application Discontinuation
- 2004-02-13 RU RU2005128551/04A patent/RU2005128551A/en not_active Application Discontinuation
- 2004-02-13 PA PA20048595901A patent/PA8595901A1/en unknown
- 2004-02-13 PE PE2004000158A patent/PE20040952A1/en not_active Application Discontinuation
- 2004-02-13 MY MYPI20040479A patent/MY139102A/en unknown
- 2004-02-13 JP JP2006501827A patent/JP2006517563A/en active Pending
- 2004-02-13 EP EP04710808A patent/EP1597228A2/en not_active Withdrawn
- 2004-02-13 CA CA002516118A patent/CA2516118A1/en not_active Abandoned
- 2004-02-13 UA UAA200508733A patent/UA86760C2/en unknown
- 2004-02-13 AU AU2004212145A patent/AU2004212145B2/en not_active Ceased
- 2004-02-13 PL PL378065A patent/PL378065A1/en not_active Application Discontinuation
- 2004-02-13 RS YUP-2005/0666A patent/RS20050666A/en unknown
- 2004-02-13 MX MXPA05008449A patent/MXPA05008449A/en active IP Right Grant
- 2004-02-13 TW TW093103412A patent/TW200510297A/en unknown
- 2004-02-13 CN CNB2004800098606A patent/CN100506792C/en not_active Expired - Fee Related
- 2004-02-13 WO PCT/EP2004/001342 patent/WO2004072025A2/en active Search and Examination
- 2004-02-13 BR BRPI0407504-8A patent/BRPI0407504A/en not_active IP Right Cessation
- 2004-02-13 OA OA1200500227A patent/OA13027A/en unknown
- 2004-02-16 AR ARP040100469A patent/AR044496A1/en unknown
-
2005
- 2005-08-10 ZA ZA200506369A patent/ZA200506369B/en unknown
- 2005-08-11 CO CO05079788A patent/CO5690548A2/en not_active Application Discontinuation
- 2005-08-11 EC EC2005005967A patent/ECSP055967A/en unknown
- 2005-08-11 MA MA28430A patent/MA27735A1/en unknown
- 2005-08-12 TN TNP2005000194A patent/TNSN05194A1/en unknown
- 2005-08-12 HR HR20050710A patent/HRP20050710A2/en not_active Application Discontinuation
- 2005-09-12 NO NO20054220A patent/NO20054220L/en unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA05008449A (en) | 2006-05-25 |
UY28186A1 (en) | 2004-09-30 |
NO20054220D0 (en) | 2005-09-12 |
CA2516118A1 (en) | 2004-08-26 |
PA8595901A1 (en) | 2004-09-16 |
RU2005128551A (en) | 2006-02-10 |
TNSN05194A1 (en) | 2007-06-11 |
HRP20050710A2 (en) | 2006-07-31 |
WO2004072025A3 (en) | 2004-12-23 |
DE10306250A1 (en) | 2004-09-09 |
NO20054220L (en) | 2005-10-28 |
CO5690548A2 (en) | 2006-10-31 |
NZ541823A (en) | 2009-01-31 |
EP1597228A2 (en) | 2005-11-23 |
ZA200506369B (en) | 2006-07-26 |
AU2004212145B2 (en) | 2010-06-17 |
AU2004212145A1 (en) | 2004-08-26 |
ECSP055967A (en) | 2006-01-16 |
TW200510297A (en) | 2005-03-16 |
MA27735A1 (en) | 2006-02-01 |
CN100506792C (en) | 2009-07-01 |
UA86760C2 (en) | 2009-05-25 |
AR044496A1 (en) | 2005-09-14 |
JP2006517563A (en) | 2006-07-27 |
OA13027A (en) | 2006-11-10 |
BRPI0407504A (en) | 2006-02-14 |
PL378065A1 (en) | 2006-02-20 |
RS20050666A (en) | 2007-12-31 |
CN1774418A (en) | 2006-05-17 |
WO2004072025A2 (en) | 2004-08-26 |
KR20050101215A (en) | 2005-10-20 |
MY139102A (en) | 2009-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20040952A1 (en) | N-ARYLHETERO CYCLES SUBSTITUTED AND PROCEDURES FOR THEIR PREPARATION | |
RU2436776C2 (en) | DIARYLAMINE-CONTAINING COMPOUNDS, COMPOSITIONS AND USE THEREOF AS c-KIT RECEPTOR MODULATORS | |
PE20070462A1 (en) | COMPOUNDS DERIVED FROM PHENYLAMINE PROPANOL | |
PE20040702A1 (en) | SUBSTITUTE DIARY HETEROCYCLES AND PROCEDURE FOR THEIR PREPARATION AS MEDICINES | |
AR049124A1 (en) | PIRIMIDINONE COMPOUNDS AS INHIBITORS OF THE INTEGRESS OF HIV VIRUS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF AIDS AND HIV INFECTION | |
PE20071245A1 (en) | INDOL SULFONAMIDE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMs) | |
AR055165A1 (en) | NS5B INDOLOBENZACEPIN HCV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF HEPATITIS C. | |
NO20063470L (en) | Tetrazole compounds and their use of metabotrophic glutamate receptor antagonists | |
PE20061316A1 (en) | PIRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS | |
PE20081475A1 (en) | ARILAMIDES SUBSTITUTED BY THIAZOL OR OXAZOLE | |
PE20080522A1 (en) | INHIBITORS OF INHIBITORS OF SODIUM DEPENDENT GLUCOSE TRANSPORTERS (SGLT) | |
CO5680407A2 (en) | NEW KINASE INHIBITORS | |
PE20090434A1 (en) | SULFONIL AMIDE DERIVATIVES AS KINASE INHIBITORS | |
RS51137B (en) | Benzimidazole derivative and its use as aii receptor antagonist | |
AR054341A1 (en) | SYNERGIC COMBINATIONS OF FUNGICIDAL ACTIVE COMPOUNDS | |
PE20061357A1 (en) | COMPOUNDS DERIVED FROM AMINOSULFONIL AS INHIBITORS OF 11-ß-HSD-1 | |
PE20090057A1 (en) | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | |
AR056574A1 (en) | PIRAZOL DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND USE PROCEDURES | |
TNSN06203A1 (en) | Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity | |
NO20063469L (en) | Polyeheterocyclic compounds and their use as metabotrophic glutamate receptor antagonists | |
NO20051223L (en) | Oxadiazoles as modulators of metabotropic glutamate receptor-5. | |
PE20040898A1 (en) | NEW COMPOUNDS DERIVED FROM PYRIMIDINE | |
AR052972A1 (en) | CARBOXAMID DERIVATIVES AS AGENTS AGAINST PATHOGEN FUNGI | |
NO20076638L (en) | New 8-sulfonylamino-3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating the 5HT6 receptor | |
AR057408A1 (en) | NIACINE RECEIVER AGONISTS COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal | ||
FG | Grant, registration | ||
FD | Application declared void or lapsed |